Replies to post #332520 on Anavex Life Sciences Corp (AVXL)

[Bourbon_on_my_cornflakes]

George, I agree that mgt has certainly moved the ball well between the 20 years lines, as your chart shows.

But until they put one in the end zone, the jury is out on how well they are doing.

I like all these scoring drives, but no points (no approvals), not even a field goal (definitive big trial results) keeps the stock price from scoring with investors.

[RipperMagoo1]

I recall a few months back CM saying that a new PD trial would be pivotal (along with a PDD pivotal trial). If that jibes with other's memories, does anyone know why they they are only designing only a P2 per the pipeline image? Why not go straight to a 2b/3 or P3? If we get an NDA for Rett and others, shouldn't we only be turning out pivotal trials for each new disease indication? TIA